NASDAQ:NCNA

NuCana - NCNA Stock Forecast, Price & News

$0.85

+0.05 (+6.19%)

(As of 03/28/2023 04:00 PM ET)

Add

Compare

Today's Range: $0.81
▼
$0.91
50-Day Range: $0.80
▼
$1.69
52-Week Range: $0.52
▼
$2.24

Volume: 252,558 shs
Average Volume: 158,608 shs
Market Capitalization: $44.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.67

Institutional Ownership

NuCana MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 329.9% Upside
$3.67 Price Target
Short Interest: Healthy
0.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.07
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.53) to ($0.41) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

436th out of 1,002 stocks

Pharmaceutical Preparations Industry

204th out of 488 stocks

3.5

Analyst's Opinion

Consensus Rating
NuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.67, NuCana has a forecasted upside of 329.9% from its current price of $0.85.
Amount of Analyst Coverage
NuCana has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.28% of the float of NuCana has been sold short.
Short Interest Ratio / Days to Cover
NuCana has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NuCana has recently increased by 55.47%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
NuCana does not currently pay a dividend.
Dividend Growth
NuCana does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NCNA.

1.7

News and Social Media Coverage

News Sentiment
NuCana has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for NuCana this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NCNA on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added NuCana to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NuCana insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.53% of the stock of NuCana is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NuCana are expected to grow in the coming year, from ($0.53) to ($0.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NuCana is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NuCana is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NuCana has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NuCana (NASDAQ:NCNA) Stock

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NCNA Stock News Headlines

March 24, 2023 | finance.yahoo.com

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid

March 24, 2023 | finance.yahoo.com

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

March 28, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

March 14, 2023 | msn.com

Bank Stocks Boost European Equities Sharply Higher in Tuesday Trading

March 13, 2023 | msn.com

Financial Stocks Weigh Down European Equities in Monday Trading

March 9, 2023 | msn.com

Telcoms Stocks Nudge European Equities Slightly Lower in Thursday Trading

January 3, 2023 | finance.yahoo.com

NuCana to Host Investor Meetings During the J.P. Morgan Healthcare Conference

December 20, 2022 | finance.yahoo.com

NuCana plc (NCNA) Stock Historical Prices & Data - Yahoo Finance

March 28, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

November 16, 2022 | finance.yahoo.com

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

November 8, 2022 | finanznachrichten.de

NuCana plc: NuCana to Present at the Jefferies London Healthcare Conference

November 8, 2022 | finance.yahoo.com

NuCana to Present at the Jefferies London Healthcare Conference

October 26, 2022 | finance.yahoo.com

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

October 15, 2022 | nz.finance.yahoo.com

Is NuCana (NASDAQ:NCNA) In A Good Position To Deliver On Growth Plans?

October 5, 2022 | nasdaq.com

Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Nasdaq

October 3, 2022 | reuters.com

NCNA.OQ - NuCana PLC (ADR) | Stock Price & Latest News | Reuters

September 28, 2022 | nasdaq.com

NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq

September 28, 2022 | finance.yahoo.com

Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

September 23, 2022 | uk.investing.com

Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday By Benzinga - Investing.com UK

September 23, 2022 | seekingalpha.com

NuCana Stock: An Intriguing 'Sum Of The Parts' Story (NASDAQ:NCNA) - Seeking Alpha

September 13, 2022 | finance.yahoo.com

NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 - Yahoo Finance

September 12, 2022 | benzinga.com

NuCana (NASDAQ:NCNA) – NuCana Presents Data On NUC-7738 At The European Society Of Medical Oncology Annua - Benzinga

September 12, 2022 | benzinga.com

NuCana (NASDAQ:NCNA) – NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Onco - Benzinga

September 12, 2022 | globenewswire.com

NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 - GlobeNewswire

September 12, 2022 | finance.yahoo.com

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

September 12, 2022 | finanznachrichten.de

NuCana plc: NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

September 12, 2022 | finance.yahoo.com

NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NCNA Company Calendar

Last Earnings: 11/17/2021
Today: 3/28/2023
Next Earnings (Estimated): 4/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NCNA
CUSIP: N/A
CIK: 1709626
Web: www.nucana.com
Phone: 441313571111
Fax: N/A
Employees: 27
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.67
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +356.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,740,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -52.95%
Return on Assets: -43.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.04
Quick Ratio: 4.04

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.73 per share
Price / Book: 0.46

Miscellaneous

Outstanding Shares: 52,180,000
Free Float: 35,900,000
Market Cap: $41.91 million
Optionable: Not Optionable
Beta: 1.29

Key Executives

Hugh Stephen Griffith
Chief Executive Officer & Executive Director

Donald Munoz
Chief Financial Officer

Elisabeth Oelmann
Senior VP-Medical & Clinical Development

Jeffrey D. Bloss
Chief Medical Officer

Theresa Margaret Bruce
Senior Vice President-Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NCNA Stock - Frequently Asked Questions

Should I buy or sell NuCana stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings or view top-rated stocks.
What is NuCana's stock price forecast for 2023?: 1 Wall Street research analysts have issued 12 month price targets for NuCana's stock. Their NCNA share price forecasts range from $2.00 to $6.00. On average, they predict the company's share price to reach $3.67 in the next twelve months. This suggests a possible upside of 356.5% from the stock's current price.
View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts.
How have NCNA shares performed in 2023?: NuCana's stock was trading at $0.66 at the start of the year. Since then, NCNA stock has increased by 21.7% and is now trading at $0.8032.
View the best growth stocks for 2023 here.
Are investors shorting NuCana?: NuCana saw a increase in short interest in March. As of March 15th, there was short interest totaling 118,000 shares, an increase of 55.5% from the February 28th total of 75,900 shares. Based on an average trading volume of 141,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.3% of the company's stock are short sold.
View NuCana's Short Interest.
When is NuCana's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our NCNA earnings forecast.
How were NuCana's earnings last quarter?: NuCana plc (NASDAQ:NCNA) posted its quarterly earnings data on Wednesday, November, 17th. The company reported ($15.00) earnings per share for the quarter, topping the consensus estimate of ($18.50) by $3.50.

What other stocks do shareholders of NuCana own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Pfizer (PFE), Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH).
When did NuCana IPO?: (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.
What is NuCana's stock symbol?: NuCana trades on the NASDAQ under the ticker symbol "NCNA."
Who are NuCana's major shareholders?: NuCana's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.63%) and Susquehanna International Group LLP (0.12%).
How do I buy shares of NuCana?: Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NuCana's stock price today?: One share of NCNA stock can currently be purchased for approximately $0.80.
How much money does NuCana make?: NuCana (NASDAQ:NCNA) has a market capitalization of $41.91 million. The company earns $-55,740,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.
How can I contact NuCana?: NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The official website for the company is www.nucana.com. The company can be reached via phone at 441313571111 or via email at chris.brinzey@westwicke.com.

This page (NASDAQ:NCNA) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NuCana - NCNA Stock Forecast, Price & News

NuCana MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About NuCana (NASDAQ:NCNA) Stock

NCNA Stock News Headlines

NCNA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

NCNA Stock - Frequently Asked Questions

Overall MarketRank^™